Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Get Free Report) passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.76 and traded as high as $0.98. Brainstorm Cell Therapeutics shares last traded at $0.9727, with a volume of 22,429 shares traded.
Brainstorm Cell Therapeutics Stock Down 4.9%
The stock has a 50 day simple moving average of $0.87 and a 200 day simple moving average of $0.76. The company has a market capitalization of $9.89 million, a price-to-earnings ratio of -0.27 and a beta of 0.23.
Brainstorm Cell Therapeutics Company Profile
BrainStorm Cell Therapeutics Inc (NASDAQ: BCLI) is a clinical‐stage biotechnology company focused on developing autologous cell therapies for the treatment of neurodegenerative diseases. The company’s proprietary platform leverages mesenchymal stem cells (MSCs) that are engineered to secrete neurotrophic and growth factors designed to support neuronal survival and function.
The company’s lead product candidate, NurOwn, is an autologous MSC therapy currently in advanced clinical development for amyotrophic lateral sclerosis (ALS).
Featured Articles
- Five stocks we like better than Brainstorm Cell Therapeutics
- AST SpaceMobile Stock Sinks as SpaceX Fallout Rattles Space Sector
- Aehr Test Systems Stock Soars on Earnings, Eyes Over 150% Revenue Growth
- TSMC Just Gave AI Chip Bulls Another Reason to Stay Confident
- GE Aerospace Faces a Prove-It Moment in Q2 Earnings
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
